Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.

ABSTRACT:

Objective

To investigate whether women and men with Parkinson disease (PD) differ in their biochemical and clinical responses to long-term treatment with inosine.

Methods

The Safety of Urate Elevation in Parkinson's Disease (SURE-PD) trial enrolled 75 people with early PD and baseline serum urate below 6 mg/dL and randomized them to 3 double-blinded treatment arms: oral placebo or inosine titrated to produce mild (6.1-7.0 mg/dL) or moderate (7.1-8.0 mg/dL) serum urate elevation for up to 2 years. Parkinsonism, serum urate, and plasma antioxidant capacity were measured at baseline and repeatedly on treatment; CSF urate was assessed once, at 3 months. Here in secondary analyses results are stratified by sex.

Results

Inosine produced an absolute increase in average serum

SUBMITTER: Schwarzschild MA 

PROVIDER: S-EPMC6814412 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature